Repros Therapeutics Says FDA Granted End of Phase 2 Meeting in Late May to Discuss Proellex(R)-V Phase 2 Design
Repros Therapeutics Inc.^® (Nasdaq: RPRX) today announced that the FDA has agreed to a Type B meeting scheduled for the last half of May to discuss the Phase 3 development of Proellex® as a vaginally administered product for the treatment of uterine fibroids. During the meeting, Repros will discuss the proposed plans for a Phase 3 study, the FDA's requirements for the size of the safety population and the adequacy of the already completed preclinical studies to support a marketing application.
Once the meeting is held, the Company will report the outcome to the financial community in a timely fashion.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.